Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Mackie Research report AGN

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Feb 05, 2021 10:01pm

147 Views

Post# 32491563

RE:Mackie Research report AGN

Warning!!!!!

After reading this coverage again, not mentioning the current trial till the bottom and pumping DMT, a PP is coming, mackie did the last one and they are prepping the next.

Data Q4/21 lmao

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand